Phizer Buys VC-Backed NextWave Pharmaceuticals

Phizer is snapping up NextWave Pharmaceuticals—a company backed by a laundry list of investors including Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures. Under the terms of the deal, Pfizer will pay $255 million to NextWave’s shareholders at closing. NextWave’s shareholders are eligible to receive up to $425 million in additional money, based on sales milestones. NextWave closed a $45 million round last January.

Cebix Incorporated Inks $30.9m Series C and Appoints President and CEO

Cebix Incorporated, a biopharmaceutical company developing treatments for complications of diabetes, has secured a $30.9M Series B investment. Prior investors InterWest, Sofinnova Ventures and Thomas, McNerney & Partners all participated in the financing. The company has also appointed Dr. Joel Martin as president and CEO.

peHUB First Read

Everyone, please meet Radish the cat, peHUB’s new intern. We’re still training her to fetch coffee. Or, anything.

Alimera Sciences Inks $40m Series A led by Palo Alto Investors

Alimera Sciences, a biopharmaceutical company specialising in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has secured a $40 million Series A financing. Palo Alto Investors acted as the lead investor in the offering, with Sofinnova Ventures and New Enterprise Associates also participating. PRESS RELEASE Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that […]

Catalyst Biosciences Inks $7M from Phizer

Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.

Takeda Pharmaceutical Buys VC-Backed Intellikine

Takeda Pharmaceutical Company, a listed, Japanese pharmaceutical research company, is buying venture-backed Intellikine Inc. Takeda will pay $190 million in cash, and up to $120 million in additional milestone payments. Intellikine was backed by at least $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

peHUB First Read

Cowa-Bunga-Bunga: Berlusconi’s outta here!

L’Chaim! Sofinnova Ventures eyes Israel

Back in Action: SAC Capital spinoff Siris

They’ll be Back: Occupy Zuccotti protestors plot NY-to-DC march

Me, Too! Now Yelp wants to go public

Fund Founded: Thiel’s fund said to be raising up to $600 million

Stashing the Cash: JC Flowers weathers global market turmoil

Cloud’s Silver Lining: start-up rolls out new product and boosts management team

Bring it Back: Back9 boosts funding round

A Healthy Start: Healthcare resource start-up Kyruus raises $3 million

Intellikine Adds $4M in Milestone Payments

Biopharma company Intellikine Inc. has sealed $4 million in new milestone payments as it begins two Phase 1 clinical trials of its drugs. The company, based in La Jolla, Calif., is backed by $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

PEHUB Community

Join the 12494 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget